IP Library › Granted Patent US 12,404,310
Granted Patent B2
US 12,404,310 · App. 17/013,246 · Granted Sep 2, 2025

Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds

Inventors: Penelope R. Chua (Emeryville, CA); Hanxiao Jiang (Emeryville, CA); Adam Leon Meadows (Emeryville, CA)
Assignee: AMYRIS, INC.
C07K14/395C12N1/16C12N15/52C12N15/635C12N15/65C12P5/02C12P5/026C12P7/64C12P19/62C12P21/00C12P21/02C07K2319/95C12N2330/51C12Y503/03002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,310
App. No.
17/013,246
Granted
Sep 2, 2025
Kind
B2
Abstract

The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.

Claims (33)

1. A genetically modified host cell comprising:

a heterologous nucleic acid encoding a fusion protein comprising a protein of interest fused in frame to a maltose dependent degron,

wherein the fusion protein is most stable when the maltose dependent degron is in contact with a maltose based inducer compared to when the maltose dependent degron is not in contact with the maltose based inducer,

wherein the maltose degron in the fusion protein comprises:

i. the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28;

ii. amino acid residues 1-365 of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28; or

iii. a homolog comprising at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28; and

wherein the maltose dependent degron further comprises one or more variant amino acid residue substitutions selected from the group consisting of K7R, I10T, W11G, L21S, V24A, F28Y, D42V, K43E, A64T, F68S, D83G, D88N, P92T, W95R, V98I, N101I, A110T, I117V, P134S, A135T, L136M, M149I, Y168C, Y168N, Y177H, N186S, A187P, L193S, D198V, D210E, A216V, A217D, G229C, I236N, D237N, N242D, L263M, L291V, A304S, T321N, M322L, A339T, A351T, T357S, T367S, S370P, and N374S, wherein said one or more variant amino acid residue substitutions correspond to the amino acid positions of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28.

2. The genetically modified host cell of claim 1 , wherein the heterologous nucleic acid is operably linked to a maltose-responsive promoter.

3. The genetically modified host cell of claim 1 , further comprising one or more heterologous nucleic acids encoding one or more enzymes of a biosynthetic pathway for making a heterologous non-catabolic compound.

4. The genetically modified host cell of claim 1 , wherein the genetically modified host cell is selected from the group consisting of a fungal cell, a bacterial cell, a plant cell, and an animal cell.

5. The genetically modified host cell of claim 4 , wherein the genetically modified host cell is a yeast cell.

6. The genetically modified host cell of claim 2 , wherein the maltose-responsive promoter is a synthetic maltose-responsive promoter.

7. The genetically modified host cell of claim 2 , wherein the maltose-responsive promoter comprises a sequence selected from the group consisting of: pMAL1 (SEQ ID NO: 29), pMAL2 (SEQ ID NO: 30), pMALL1 (SEQ ID NO: 31), pMAL12 (SEQ ID NO: 32), pMAL31 (SEQ ID NO: 33), pMAL32 (SEQ ID NO: 34), pMAL32_v1 (SEQ ID NO: 78), pGMAL_v5 (SEQ ID NO: 35), pGMAL_v6 (SEQ ID NO: 36), pGMAL_v7 (SEQ ID NO: 37), pGMAL_v9 (SEQ ID NO: 38), pGMAL_v10 (SEQ ID NO: 39), pGMAL_v11 (SEQ ID NO: 40), pGMAL v12 (SEQ ID NO: 41, pGMAL_v13 (SEQ ID NO: 42), pGMAL_v14 (SEQ ID NO: 43), pGMAL v15 (SEQ ID NO: 44), pGMAL_v16 (SEQ ID NO: 45), pG@MAL v17 (SEQ ID NO: 46), p@MAL_v18 (SEQ ID NO: 47), pG2MAL v1 (SEQ ID NO: 48), pG2MAL_v2 (SEQ ID NO: 49), pG2MAL_v3 (SEQ ID NO: 50), pG2MAL_v5 (SEQ ID NO: 51), pG2MAL v6 (SEQ ID NO: 52), pG2MAL_v7 (SEQ ID NO: 53), pG2MAL_v8 (SEQ ID NO: 54), pG2MAL v9 (SEQ ID NO: 55), pG2MAL v10 (SEQ ID NO: 56), pG7MAL_v2 (SEQ ID NO: 57), pG7MAL v4 (SEQ ID NO: 58), pG7MAL_v6 (SEQ ID NO: 59), pG7MAL v8 (SEQ ID NO: 60), pG7MAL_v9 (SEQ ID NO: 61), pG172_MAL_v13 (SEQ ID NO: 62), pG271_MAL v12 (SEQ ID NO: 63), pG721_MAL v11 (SEQ ID NO: 64), pG712_MAL v14 (SEQ ID NO: 63).

8. The genetically modified host cell of claim 1 , wherein the maltose dependent degron is truncated after position corresponding to position 365 of the amino acid sequence of SEQ ID NO: 2.

9. The genetically modified host cell of claim 1 , wherein the one or more variant amino acid residue substitutions are selected from the group consisting of I10T, V24A, D42V, M149I, and C216V.

10. The genetically modified host cell of claim 1 , wherein the maltose dependent degron comprises at least one set of variant amino acid residue substitutions, and wherein the at least one set of variant amino acid residue substitutions is selected from the group consisting of:

(a) I10T, V24A, D42V, K43E, D83G, P92T, M149I, Y168N, N186S, A216V, and T357S;

(b) I10T, V24A, D42V, K43E, D83G, M149I, Y168N, N186S, A216V, and D237N;

(c) I10T, V24A, D42V, K43E, D83G, M149I, Y168N, N186S, A216V, and A339T;

(d) I10T, V24A, D42V, K43E, D83G, M149I, Y168N, N186S, A216V, and N242D;

(e) I10T, V24A, D42V, A110T, M149I, and A216V;

(f) I10T, V24A, D42V, K43E, D83G, M149I, Y168N, N186S, and A216V;

(g) L21S, A64T, L136M, Y177H, A187P, A304S, T321N, and A351T;

(h) K7R, D83G, V98I, L193S, I236N, and N374S;

(i) WIIG, D&88N, P1348, A135T, D210E, and M322L;

(j) U17V, Y168N, G229C, L263M, T367S, and S370P;

(k) F68S, W95R, N186S, and DI98V; and

(l) F28Y, K43E, NIOLL, Y168C, A217D, and L291V.

11. A fermentation composition comprising the genetically modified host cell of claim 1 in a culture medium comprising the maltose based inducer.

12. An isolated nucleic acid molecule encoding a maltose dependent degron or a homolog thereof, comprising an amino acid sequence having at least 90 or 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28; wherein:

(a) the maltose dependent degron or homolog thereof comprises one or more variant amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28, and

(b) the one or more variant amino acid substitutions are selected from the group of K7R, 110T, W11G, L21S, V24A, F28Y, D42V, K43E, A64T, F68S, D83G, D88N, P92T, W95R, V98I, N101I, A110T, I117V, P134S, A135T, L136M, M149I, Y168C, Y168N, Y177H, N186S, A187P, L193S, D198V, D210E, A216V, A217D, G229C, I236N, D237N, N242D, L263M, L291V, A304S, T321N, M322L, A339T, A351T, T357S, T367S, S370P, and N374S, wherein said one or more variant amino acid residue substitutions correspond to the amino acid positions of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 28.

Assignments (8)
SECURITY INTEREST Recorded Oct 6, 2025
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 072483/0112 →
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062310/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: CHUA, PENELOPE R.; JIANG, HANXIAO; MEADOWS, ADAM LEON
To: AMYRIS, INC.; TOTAL MARKETING SERVICES
Reel/Frame 061732/0562 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
SECURITY INTEREST Recorded Mar 10, 2021
From: AMYRIS, INC., AS GRANTOR
To: NAXYRIS S.A., AS LENDER
Reel/Frame 055547/0529 →
Continuity (4)
Division 15738555
Provisional Application 62184793 · Jun 25, 2015
Provisional Application 62266436 · Dec 11, 2015
Related Publication 20200399326A1 · Dec 24, 2020
References Cited (23)
US 20020156001A1 · Econs et al. · 2002 [cited by applicant]
US 20060141570A1 · Wood et al. · 2006 [cited by applicant]
US 20070243579A1 · Sedgwick et al. · 2007 [cited by applicant]
US 20090305342A1 · Riggs et al. · 2009 [cited by applicant]
US 20180171341A1 · Chua et al. · 2018 [cited by applicant]
EP 3313996A1 · 2018 [cited by applicant]
WO WO2010114532A1 · 2010 [cited by applicant]
WO WO2014025941A1 · 2014 [cited by applicant]
WO WO2015020649A1 · 2015 [cited by applicant]
Singh RK et al. Protein Engineering Approaches in the Post-Genomic Era. 2017. Current Protein and Peptide Science. 18, 1-11. (Year: 2017). [cited by examiner]
Zhang M et al. Propagated Perturbations from a Peripheral Mutation Show Interactions Supporting WW Domain Thermostability. 2018. Structure. 26, 1474-1485. (Year: 2018). [cited by examiner]
International Search report and written opinion mailed on Aug. 29, 2016 for PCT/US2016/039386, 16 pages. [cited by applicant]
Dokholyan, “Controlling allosteric networks in proteins”, Chemical Reviews, vol. 116, Feb. 19, 2016, pp. 6463-6487. [cited by applicant]
Jiang et al., “Controlling isoprenoid production using a microaerobic-responsive switch in yeast”, Genetics Society of America Conferences, Yeast Genetics Meeting, 2014, University of Washington, Seattle, Abstracts Book… [cited by applicant]
Makhlynets et al., “Design of allosterically regulated protein catalysts”, Biochemistry, vol. 54, Feb. 2, 2015, pp. 1444-1456. [cited by applicant]
New et al., “Different levels of catabolite repression optimize growth in stable and variable environments”, Plos Biology, vol. 12, 2014, pp. 1-22. [cited by applicant]
Platt, “Dawn of a golden age formicrobial engineering”, World Congress on Industrial Biotechnology; Montreal, Jul. 2015, Presentation paper, Jul. 2015, pp. 1-32, Retrieved from the Internet: URL:https://www.bio.org/site… [cited by applicant]
Sandoval et al., “Use of pantothenate as a metabolic switch increases the genetic stability of farnesene producing [cited by applicant]
Walker et al., “Mutations in maltose-binding protein that alter affinity and solubility properties”, Applied Microbiology and Biotechnology, vol. 88, 2010, pp. 187-197. [cited by applicant]
Weinhandl et al., “Carbon source dependent promoters in yeast”, Microbial Cell Factories, vol. 13, 2014, pp. 1-17. [cited by applicant]
Communication pursuant to Article 94(3) EPC issued in corresponding European Patent Application No. 16 734 852.3, dated Jun. 12, 2020. [cited by applicant]
Rienzo et al., “Different mechanisms confer gradual control and memory at nutrient- and stress-regulated genes in yeast”, Molecular and Cellular Biology, vol. 35, Aug. 17, 2015, pp. 3669-3683, XP-002760450. [cited by applicant]
Choi et al., “Design of protein switches based on an ensemble model of allostery”, Nature Communications, 6:6968, Apr. 22, 2015, pp. 1-9, XP002760503, DOI: 10.1038/ncomms7968. [cited by applicant]